Open Daily: 10am - 10pm | Alley door pickup 10am - 7pm 3038 Hennepin Ave Minneapolis, MN
612-822-4611

  • Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
Current management of chronic myelogenous leukemia

Current management of chronic myelogenous leukemia

Siali, Nadjat
Fettal, Nadia

Paperback

Medical Reference

ISBN10: 6207833570
ISBN13: 9786207833573
Publisher: Our Knowledge Publishing
Published: May 27 2025
Pages: 144
Weight: 0.44
Height: 0.34 Width: 6.00 Depth: 9.00
Language: English
Chronic myeloid leukemia constitutes a model in Onco-hematology, because it was the first chromosomal anomaly described in a malignant disease, but whose leukemogenesis has been particularly well studied, thus allowing major therapeutic advances. It is associated with a recurrent genetic anomaly: the Philadelphia chromosome, balanced reciprocal translocation t (9; 22), which results in a BCR-ABL fusion gene, then an abnormal protein with tyrosine kinase activity, responsible for leukemic transformation. It is also the first disease where molecular targeted therapy has been used successfully; including imatinib; these TKIs showed most mutations, except the dreaded T315I mutation. This led scientists to develop a third generation TKI; It's Ponatinib. These outpatient treatments allowed for better hematological, cytogenetic and molecular responses, associated with a better quality of life for patients. However, TKIs do not eradicate the disease. However, allogeneic hematopoietic stem cell transplantation remains the only curative treatment at present.

Also from

Siali, Nadjat

View All

Also in

Medical Reference

View All